The Technical Analyst
Genfit SA [GNFT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Genfit SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.35% $3.49
America/New_York / 26 apr 2024 @ 11:44
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 173.41 mill |
| EPS: | -0.610 |
| P/E: | -5.72 |
| Earnings Date: | Sep 19, 2024 |
| SharesOutstanding: | 49.69 mill |
| Avg Daily Volume: | 0.0061 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | n/a | n/a | ||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.72 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.97x |
| Company: PE -5.72 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.32 - 3.66 ( +/- 4.96%) |
| ATR Model: 14 days |
Forecast:
13:24 - $3.47
Live Trading Signals (every 1 min)
Forecast
1: 11:54 - $3.48
Forecast 2: 12:44 - $3.47
Forecast 3: 13:24 - $3.47
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $3.49 (2.35% ) |
| Volume | 0.0013 mill |
| Avg. Vol. | 0.0061 mill |
| % of Avg. Vol | 21.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GNFT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GNFT
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Latest Press Releases
2024-04-25 16:10:00 - Press Release
Genfit: Publication Of The 2024 Extra-financial Performance Report (fiscal Year 2023)
Lille (france), cambridge (massachusetts, usa), zurich (switzerland), april 25, 2024 - genfit (nasdaq and euronext: gnft), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 extra-financial performance report (fiscal year 2023).
2024-04-15 16:10:00 - Press Release
Genfit Annual Combined General Meeting Of May 22, 2024 — Availability Of Preparatory Documents
Lille (france); cambridge (massachusetts, united states); zurich (switzerland); april 15, 2024 - genfit (nasdaq and euronext: gnft), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the april 15, 2024 french legal announcements bulletin n°46 (bulletin des annonces lÉgales obligatoires) its convening notice that the combined shareholders meeting will be held on may 22, 2024, at 10:00am (cet), at the faculty of pharmaceutical sciences in lille, located at parc eurasantÉ, 3 rue du professeur laguesse, 59000 lille, france.
2024-04-05 14:00:00 - Press Release
Genfit Announces Publication Of The 2023 Universal Registration Document And The 2023 Annual Report On Form 20-f
Lille (france), cambridge (massachusetts, united states), zurich (switzerland), april 5, 2024 - genfit (nasdaq and euronext: gnft), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the filing of its 2023 universal registration document with the autoritÉ des marchÉs financiers (amf ; filing n° d.24-0246) and its annual report on form 20-f for the year ended december 31, 2023 with the u.s. securities and exchange commission (sec).
2024-04-04 16:10:00 - Press Release
Genfit Reports Full-year 2023 Financial Results And Provides Corporate Update
Lille, france; cambridge, ma; zurich, switzerland; april 4, 2024 - genfit (nasdaq and euronext: gnft), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended december 31, 2023. a summary of the consolidated financial statements is included below.
2024-02-29 16:10:00 - Press Release
Genfit Announces Revenues And Cash Position As Of December 31, 2023
Lille (france), cambridge (massachusetts, united states), zurich (switzerland), february 29, 2024 - genfit (nasdaq and euronext: gnft), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of december 31, 2023 and revenues for 2023.
Latest News
2023-11-27 07:30:00 - Seeking Alpha
Genfit: Large PBC Market, Liquidity To Await Approval
Genfit is close to possible approval for its drug team-up with Ipsen, with positive Phase 3 readouts having been achieved. The company focuses on developing therapeutic products for liver diseases, currently with a primary focus on Primary Biliary Cholangitis (PBC). Genfit's cash situation is decent, with most of its debt being convertible and maturing in a distant enough future, giving the company time for key approvals.
2023-11-02 17:10:00 - GlobeNewsWire
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present an update on its scientific and corporate progress at The Liver Meeting® 2023 organized by the American Association for the Study of Liver Diseases (AASLD), which will take place in Boston, MA (USA) from November 10-14, 2023.
2023-09-05 16:10:00 - GlobeNewsWire
GENFIT to Participate in Upcoming Investor Conferences
Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) , September 05 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences.
2023-06-30 10:46:07 - Proactive Investors
Genfit shares fall despite positive trial results for rare cholestatic liver disease therapeutic
GENFIT (NASDAQ:GNFT) shares fell 5% after initially rising on positive results from its clinical trial with partner Ipsen for the investigational therapeutic elafibranor in patients with the rare cholestatic liver disease primary biliary cholangitis (PBC). The two companies announced on Friday that the Phase 3 ELATIVE trial met its primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to the placebo.
2023-06-30 06:44:00 - Market Watch
U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease
The U.S.-listed stock of Genfit S.A. GNFT, -5.48% GNFT, +22.56% soared 27% premarket Friday, after the French biotech and partner Ipsen IPSEY, +7.22% IPN, +0.27% announced positive results from a late-stage trial of a treatment for a rare liver disease.
2023-02-10 08:47:25 - Seeking Alpha
Genfit: Catching Strong Bid With Emerging Data (Technical Analysis)
Genfit is a relatively low-beta play offering investors tactical upside with a potential re-rating to the upside. Investors have rewarded the company's pipeline assets to date, in addition to emerging data from its non-invasive technologies.
2023-02-07 13:51:59 - InvestorPlace
The 7 Best Biotech Stocks to Buy for February 2023
While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.
2022-09-07 11:52:50 - Seeking Alpha
Genfit S.A.: A 'Sum Of The Parts' Story
Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward.
2022-04-14 13:33:18 - Zacks Investment Research
What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock
GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
2022-04-08 10:24:04 - Seeking Alpha
Genfit SA (GNFT) CEO Pascal Prigent on Q4 2021 Results - Earnings Call Transcript
